Yolanda Mares-Gutiérrez , Adrián Martínez-González , Guillermo Salinas-Escudero , Manuel García-Minjares , Stephanie Liu , Yvonne N. Flores
{"title":"在墨西哥,将肺活量测定与 ARISCAT 呼吸风险评估相结合可改善术后效果并降低死亡风险","authors":"Yolanda Mares-Gutiérrez , Adrián Martínez-González , Guillermo Salinas-Escudero , Manuel García-Minjares , Stephanie Liu , Yvonne N. Flores","doi":"10.1016/j.opresp.2024.100325","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><p>Although a major goal of preoperative evaluation is to identify risk factors and improve postoperative outcomes, current clinical guidelines in Mexico indicate that preoperative spirometry should only be performed on patients with pulmonary disease. The aim of this study was to compare the incidence of postoperative complications (POC), mortality, and risk factors among adults who did or did not undergo preoperative spirometry, based on their Assess Respiratory Risk in Surgical Patients in Catalonia (ARISCAT) risk level.</p></div><div><h3>Material and methods</h3><p>An observational, retrospective and comparative study design was used to identify 2059 patients from the <em>General Hospital of Mexico</em> who had an ARISCAT assessment during 2013–2017. Patients were classified in two groups: ARISCAT with spirometry (<em>n</em> <!-->=<!--> <!-->1306) and ARISCAT without spirometry (<em>n</em> <!-->=<!--> <!-->753). Chi-square, Fisher's exact test and the Student's <em>t</em>-tests were used to compare groups. Logistic regression was used to identify factors associated with an increased risk of POC and mortality.</p></div><div><h3>Results</h3><p>In the ARISCAT with spirometry group, 11% of patients had POC, compared with 48% of patients in the ARISCAT without spirometry group. High-risk ARISCAT patients who did not receive spirometry had higher mortality (18%), than those who underwent spirometry (0.4%). Logistic regression results indicate that not performing preoperative spirometry increases the probability of POC and mortality.</p></div><div><h3>Conclusions</h3><p>Our findings suggest that the combined use of preoperative spirometry and ARISCAT is associated with reduced POC and mortality. Future clinical guidelines should recommend the use of preoperative spirometry for patients with a moderate or high ARISCAT level in Mexico.</p></div>","PeriodicalId":34317,"journal":{"name":"Open Respiratory Archives","volume":"6 3","pages":"Article 100325"},"PeriodicalIF":0.0000,"publicationDate":"2024-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2659663624000286/pdfft?md5=d0f326e798d3d29eb1cf10067ba775a3&pid=1-s2.0-S2659663624000286-main.pdf","citationCount":"0","resultStr":"{\"title\":\"Combining Spirometry and the ARISCAT Respiratory Risk Assessment Can Improve Postoperative Outcomes and Reduce Mortality Risk in Mexico\",\"authors\":\"Yolanda Mares-Gutiérrez , Adrián Martínez-González , Guillermo Salinas-Escudero , Manuel García-Minjares , Stephanie Liu , Yvonne N. Flores\",\"doi\":\"10.1016/j.opresp.2024.100325\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Introduction</h3><p>Although a major goal of preoperative evaluation is to identify risk factors and improve postoperative outcomes, current clinical guidelines in Mexico indicate that preoperative spirometry should only be performed on patients with pulmonary disease. The aim of this study was to compare the incidence of postoperative complications (POC), mortality, and risk factors among adults who did or did not undergo preoperative spirometry, based on their Assess Respiratory Risk in Surgical Patients in Catalonia (ARISCAT) risk level.</p></div><div><h3>Material and methods</h3><p>An observational, retrospective and comparative study design was used to identify 2059 patients from the <em>General Hospital of Mexico</em> who had an ARISCAT assessment during 2013–2017. Patients were classified in two groups: ARISCAT with spirometry (<em>n</em> <!-->=<!--> <!-->1306) and ARISCAT without spirometry (<em>n</em> <!-->=<!--> <!-->753). Chi-square, Fisher's exact test and the Student's <em>t</em>-tests were used to compare groups. Logistic regression was used to identify factors associated with an increased risk of POC and mortality.</p></div><div><h3>Results</h3><p>In the ARISCAT with spirometry group, 11% of patients had POC, compared with 48% of patients in the ARISCAT without spirometry group. High-risk ARISCAT patients who did not receive spirometry had higher mortality (18%), than those who underwent spirometry (0.4%). Logistic regression results indicate that not performing preoperative spirometry increases the probability of POC and mortality.</p></div><div><h3>Conclusions</h3><p>Our findings suggest that the combined use of preoperative spirometry and ARISCAT is associated with reduced POC and mortality. Future clinical guidelines should recommend the use of preoperative spirometry for patients with a moderate or high ARISCAT level in Mexico.</p></div>\",\"PeriodicalId\":34317,\"journal\":{\"name\":\"Open Respiratory Archives\",\"volume\":\"6 3\",\"pages\":\"Article 100325\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-04-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S2659663624000286/pdfft?md5=d0f326e798d3d29eb1cf10067ba775a3&pid=1-s2.0-S2659663624000286-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Open Respiratory Archives\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2659663624000286\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Open Respiratory Archives","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2659663624000286","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
Combining Spirometry and the ARISCAT Respiratory Risk Assessment Can Improve Postoperative Outcomes and Reduce Mortality Risk in Mexico
Introduction
Although a major goal of preoperative evaluation is to identify risk factors and improve postoperative outcomes, current clinical guidelines in Mexico indicate that preoperative spirometry should only be performed on patients with pulmonary disease. The aim of this study was to compare the incidence of postoperative complications (POC), mortality, and risk factors among adults who did or did not undergo preoperative spirometry, based on their Assess Respiratory Risk in Surgical Patients in Catalonia (ARISCAT) risk level.
Material and methods
An observational, retrospective and comparative study design was used to identify 2059 patients from the General Hospital of Mexico who had an ARISCAT assessment during 2013–2017. Patients were classified in two groups: ARISCAT with spirometry (n = 1306) and ARISCAT without spirometry (n = 753). Chi-square, Fisher's exact test and the Student's t-tests were used to compare groups. Logistic regression was used to identify factors associated with an increased risk of POC and mortality.
Results
In the ARISCAT with spirometry group, 11% of patients had POC, compared with 48% of patients in the ARISCAT without spirometry group. High-risk ARISCAT patients who did not receive spirometry had higher mortality (18%), than those who underwent spirometry (0.4%). Logistic regression results indicate that not performing preoperative spirometry increases the probability of POC and mortality.
Conclusions
Our findings suggest that the combined use of preoperative spirometry and ARISCAT is associated with reduced POC and mortality. Future clinical guidelines should recommend the use of preoperative spirometry for patients with a moderate or high ARISCAT level in Mexico.